Clinical trials: Islet Transplantation
Diabetes Mellitus, Type 1
Islet Transplantation in Patients With "Brittle" Type I Diabetes
The purpose of this study is to learn about the safety of islet transplantation for Type 1 diabetes mellitus, which may provide more normal control of blood sugar without the need for insulin shots.
- Trial name
- NCT01630850
- Testing
- Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Diabetes
UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes
The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes
- Trial name
- NCT06751199
- Testing
- human umbilical cord mesenchymal stem cells, allogeneic islet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetic Kidney Allograft
The purpose of this study is to learn about the safety of islet transplantation when performed after kidney transplantation, which may provide more normal control of blood sugar without the need for insulin shots.
- Trial name
- NCT01241864
- Testing
- Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Type 1 Diabetes Mellitus
B-Lymphocyte Immunotherapy in Islet Transplantation
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT00468442
- Testing
- Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
Islet Transplant in Patients With Type I Diabetes
The primary objective of this study is to demonstrate the safety of allogenic islet transplantation in type 1 diabetic patients performed at the University of Virginia.
- Trial name
- NCT03698396
- Testing
- Allogenic Islet Cell Transplantation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kenneth Brayman, MD
Diabetes
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
This is a single-center, phase IIT clinical trial to evaluate autologous regenerative islet transplantation for insulin-dependent diabetes mellitus.
- Trial name
- NCT05294822
- Testing
- Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Chronic Pancreatitis, Diabetes Mellitus
Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis
Randomized pilot trial of patients (n=30) undergoing Total Pancreatectomy and Islet AutoTransplant (TPIAT). Patients with islet harvest of greater than 5000 islet equivalents/kg body weight will be randomized to receive a portion…
- Conditions
- Chronic Pancreatitis, Diabetes Mellitus, Islet Cell Transplantation
- Trial name
- iSite (NCT03779139)
- Testing
- Intrahepatic islets and islets in the omental pouch, Intrahepatic islets alone, Normal Volunteers
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Type1diabetes
First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes
The current study tests the hypothesis whether genetically modified Langerhans islet cells containing insulin-producing cells from a deceased organ donor can 1. be transplanted safely and 2.
- Trial name
- NCT06239636
- Testing
- UP421
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- Per-Ola Carlsson
Type 1 Diabetes Mellitus
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
- Trial name
- NCT01999361
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Rodolfo Alejandro
Diabetes Mellitus, Type 1, Immunologic Deficiency Syndromes
Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM
This study evaluates the efficacy of sequential transplantation of umbilical cord blood stem cells and islet cells in children with monogenic immunodeficiency type 1 diabetes mellitus.
- Trial name
- NCT03835312
- Testing
- Sequential transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Fudan University
Type 1 Diabetes Mellitus
Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss
This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.
- Trial name
- NCT02000687
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Rodolfo Alejandro
Type 1 Diabetes Mellitus
Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
SPECIFIC AIMS: To reverse hyperglycemia and insulin dependency in patients with Type 1 diabetes mellitus by islet cell transplantation.
- Trial name
- NCT00315614
- Testing
- Islet Transplantation and Bone Marrow
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Miami
Diabetes Mellitus, Type 1
UVA Islet Cell Transplantation in Patients With Type I Diabetes
This protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant: Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems Group II: Islet Cell…
- Trial name
- NCT00605592
- Testing
- Pancreatic Islets of Langerhans Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Virginia
Type 1 Diabetes, Visual Impairment
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
This is a phase II prospective, interventional, open-labeled, proof-of-concept study. 2 years per participant, 2 years 6 months in total Total n=6 The primary objective is to assess the safety of human pancreatic islet…
- Trial name
- EYELETS (NCT04198350)
- Testing
- Islet implantation
- Where
- United Kingdom
- Sponsor
- Imperial College London
Diabetes Mellitus
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
The purpose of this study is to evaluate the safety and effectiveness of islet cell transplantation alone (ITA) in patients with difficult to control type I diabetes.
- Trial name
- NCT00706420
- Testing
- Islet Transplantation + Immunosuppression, Islet cell transplantation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
Type1 Diabetes Mellitus, Type2 Diabetes
Circulating Extracellular Vesicles Released by Human Islets of Langerhans
Beta-cells release extracellular vesicles (EV) and exosomes under normal and pathophysiologic conditions. These EV contain beta-cell specific autoantigens which may trigger the immune response at the initiation of type 1…
- Conditions
- Type1 Diabetes Mellitus, Type2 Diabetes, Islet Cell Transplantation
- Trial name
- NCT03106246
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Type 1 Diabetes Mellitus
B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT01049633
- Testing
- Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation
Our final objective is to develop an adoptive therapy with tolerogenic donor-specific Tr1 cells in T1D patients undergoing pancreatic islet transplantation (Tx).
- Trial name
- ECIT-1 (NCT01346085)
- Testing
- CNI free immunosuppression
- Where
- 2 sites in Italy, Switzerland
- Volunteers
- 10 people
- Sponsor
- Ospedale San Raffaele
Diabetes
Caspase Inhibition in Islet Transplantation
This is an Investigator Initiated, Phase I/II study, where Type 1 diabetic participants will receive a 14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following their first islet transplant.
- Trial name
- NCT01653899
- Testing
- IDN-6556
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Alberta
Type 1 Diabetes Mellitus
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Tegoprubart (AT-1501) is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness.
- Trial name
- Tegoprubart (NCT06305286)
- Testing
- Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago